Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-res...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., Reichman, R. C.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2000
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC89771/
https://ncbi.nlm.nih.gov/pubmed/10681363
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares